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During primary HIV infection, the kinetics of plasma virus con-
centrations and CD4+ cell counts is very complex. Parametric and
nonparametric models have been suggested for fitting repeated mea-
surements of these markers. Alternatively, mechanistic approaches
based on ordinary differential equations have also been proposed.
These latter models are constructed according to biological knowl-
edge and take into account the complex nonlinear interactions be-
tween viruses and cells. However, estimating the parameters of these
models is difficult. A main difficulty in the context of primary HIV
infection is that the date of infection is generally unknown. For some
patients, the date of last negative HIV test is available in addition to
the date of first positive HIV test (seroconverters). In this paper we
propose a likelihood-based method for estimating the parameters of
dynamical models using a population approach and taking into ac-
count the uncertainty of the infection date. We applied this method
to a sample of 761 HIV-infected patients from the Concerted Action
on SeroConversion to AIDS and Death in Europe (CASCADE).
1. Introduction. Primary Human Immunodeficiency Virus (HIV) infec-
tion is a crucial period during HIV infection history where there is a viral
burst due to the spread of the virus through target cells, mainly CD4+ T
lymphocytes (CD4). The dynamics of markers at that time is believed to
partly determine the evolution of the infection in the future [Mellors et al.
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(1995)]. For instance, the peak of viral load has been shown to be pre-
dictive of the viral setpoint, that is, the plasma HIV RNA level at which
patients often stay for several years [Lindback et al. (2000)] unless they are
treated. This viral setpoint is associated with clinical progression [Mellors
et al. (1995)].
Parametric and nonparametric descriptive models have been suggested
for fitting repeated measurements of CD4 and HIV RNA (or viral load)
[Dubin et al. (1994); Desquilbet et al. (2004); Pantazis et al. (2005); Hecht
et al. (2006); Geskus et al. (2007)]. A mechanistic approach based on ordi-
nary differential equations (ODE) has also been suggested [Phillips (1996);
De Boer and Perelson (1998)]. These mathematical models present several
advantages. First, they are based on biological knowledge. Therefore, the pa-
rameters may have direct biological meaning and the relationship between
markers is modeled through biological mechanisms rather than parametric
correlation structures. Second, this type of dynamical model is able to cap-
ture complex interaction between markers. For instance, these models can
predict the decrease of viral load following the peak as a consequence of the
limitation of target cells. The first models used in this context gave impor-
tant insights on the dynamics of the infection and how to control it [Nowak
et al. (1997b); Little et al. (1999)]. Numerous attempts to improve models
have been published [De Boer and Perelson (1998); Wick (1999); Stafford
et al. (2000)]. Most often, the parameters of these models are not estimated
and values which appear “reasonable” are chosen [Phillips (1996)]. Indeed,
estimating the parameters in such models is difficult. To improve identifiabil-
ity, random effects models (or population approach) can be used. However,
the combination of nonlinear ODE systems and random effects leads to dif-
ficult numerical problems [Putter et al. (2002); Filter, Xia and Gray (2005);
Huang, Liu and Wu (2006); Samson, Lavielle and Mentre´ (2006); Guedj,
Thie´baut and Commenges (2007a); Cao, Fussmann and Ramsay (2008)]: for
maximizing the likelihood we need to compute multiple integrals with a di-
mension equal to the number of random effects included in the model and to
solve numerically the ODE system; all steps ask for intensive computations.
The dynamics of the biomarkers during primary HIV infection is quite
complex. In the few studies where ODE models have been used in the context
of primary infection, the parameters were estimated from the viral load data
only [Kaufmann et al. (1998); Little et al. (1999); Stafford et al. (2000);
Lindback et al. (2000); Ciupe et al. (2006); Ribeiro et al. (2010)] or the
individual fit of the CD4 counts data was very bad [Murray et al. (1998)].
Moreover, these works did not use random effects models.
In the primary HIV infection context, the system is in a “trivial” equilib-
rium state without virus and it is disrupted by the introduction of a small
quantity of viruses (the “infection event”). The date of infection must thus
be known (in contrast to studies of the response to a treatment initiation
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far from the infection) if we want to compute the trajectories of markers.
However, this date is most often unknown. Generally, the only available
information is the date of the last seronegative test and first seropositive
test or first detectable HIV RNA load. In some cohort studies (such as the
Multicenter AIDS Cohort study [Munoz et al. (1992)]) the last seronega-
tive date is prospectively identified during follow-up. In most cases, patients
are seropositive at entry into the cohort and the last seronegative date is
retrospectively recorded. Usually, the date of seroconversion is imputed at
the midpoint between last negative and first positive HIV serology test [Fi-
dler et al. (2007)]. Several methods have been suggested for estimating this
date according to the marker values [Berman (1990); DeGruttola, Lange
and Dafni (1991); Dubin et al. (1994); Geskus (2000)]. Geskus et al. (2007)
performed a conditional mean imputation to estimate the date of infection
that was used as the baseline for linear mixed models.
In the present paper we propose a method for estimating the parameters
of dynamic models using a population approach taking into account the
uncertainty of the infection date. We estimate the parameters of a dynamical
model using HIV RNA and CD4 count data in a large collaboration including
cohorts of patients with a documented date of negative and positive HIV
serologies (HIV seroconverters).
There are several direct applications of such an approach. First, we can
estimate fundamental parameters such as virion clearance, the infected cell
death rate [Perelson et al. (1997)], virus infectivity [Wilson et al. (2007)]
which determines the rate at which T-cells are infected for given virus con-
centration, or the basic reproduction number R0 [Anderson and May (1991)]
which is defined as the average number of secondary infections that would
be caused by the introduction of a single infected cell into an entirely sus-
ceptible population of cells; this number reflects the ability of the infection
to spread and to persist in the organism. Second, the huge variability in the
peak level of HIV RNA and of the viral setpoint in the population [Kaufmann
et al. (1998); Little et al. (1999)] can be explained by the variability of pa-
rameters that carry a direct biological interpretation (cell death rates, virus
infectivity, virus production, . . .). Third, the effect of patient characteristics
or interventions could be assessed through their biological mechanism. For
instance, one could look at the effect of an antiretroviral regimen combining
reverse transcriptase inhibitors (blocking the infection of new cells) and pro-
tease inhibitors (generating a higher proportion of noninfectious virion) [Wu
and Ding (1999)] for defining the optimal time of treatment initiation for
each patient. It would also be interesting to look at the effect of the transmis-
sion of mutated viruses [Fidler et al. (2006)] or host genetics characteristics
[Fellay et al. (2007)] on the early dynamics. Furthermore, the probability
distribution of the date of infection could be useful at the population level
for defining the incidence of HIV infection or the rate of disease progression
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and to estimate the induction time (delay between the date of infection and
AIDS stage).
The paper is organized as follows. In Section 2 we describe a method based
on likelihood maximization for the estimation of parameters of a general
population ODE model with an unknown origin of time. In Section 3 we
describe two HIV dynamics models and we present a simulation study. In
Section 4 we show the results for a sample of 761 HIV-infected patients
from the Concerted Action on SeroConversion to AIDS and Death in Europe
(CASCADE). A conclusion is given in Section 5.
2. Statistical model and inference. All the notation used in this section
are summarized in Table 4 at the end of the manuscript.
2.1. General statistical model for systems and observations. First, we
describe the model for a known date of infection. We consider a general
ODE model [two particular models are proposed in Section 3.1, equations
(3.1) and (3.2)]; for subject i with i= 1, . . . , n, we can write dX
i(t)
dt
= f(Xi(t), ξi),
Xi(0) = h(ξi),
where Xi(t) = (Xi1(t), . . . ,X
i
K(t)) is the vector of the K components at time
t and ξi is a vector of p individual natural (or biological) parameters which
appear in the ODE system. We assume that f and h are known functions
and twice differentiable with respect to ξi.
Second, a model is introduced for the ξi to allow inter-individual variabil-
ity: {
ξ˜l
i
=Ψl(ξ
i
l ),
ξ˜l
i
= φl + z
i
lβl + b
i, l≤ p,
where Ψl is a known link function, φl is the intercept, and z
i
l is the vector
of explanatory variables associated to the fixed effects of the lth biological
parameter. The βl’s are vectors of regression coefficients associated to the
fixed effects. We assume bi ∼ N (0,Σ), where bi is the individual vector of
random effects of dimension q. Let A = (al′′l′)l′≤l′′≤q, the lower triangular
matrix with positive diagonal elements such that AA′ = Σ (Cholesky de-
composition). We can write bi =Aui with ui ∼N (0, Iq).
Third, we construct a model for the observations. Generally, we do not
directly observe all the components of Xi, but rather M ≤ K functions
of Xi; we call these functions “observable components” [see Section 3.2,
equations (3.3) and (3.4), e.g.]. We observe Y ijm, the jth measurement of
the mth observable component for subject i at date dijm. If we know the
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date of infection τ i, we can compute the time since infection tijm = d
i
jm− τ i
and we assume that
Y ijm = gm(X(t
i
jm, ξ˜
i)) + εijm, j = 1, . . . , n
i
m, m= 1, . . . ,M,
where ξ˜
i
= (ξ˜l
i
, l= 1, . . . , p) and the εijm are independent Gaussian measure-
ment errors with zero mean and variances σ2m. The gm(·),m= 1, . . . ,M , are
twice differentiable functions of RK to R.
2.2. The issue of unknown date of infection. We assume that the date
of infection τ i has a known density fτ i with a support [τ
i
inf , τ
i
sup]. We denote
by di− (resp. d
i
+) the date of last seronegative test (resp. first seroposi-
tive test) for patient i. For very long intervals it would be relevant to take
the density proportional to HIV incidence. Since we work with intervals
of moderate length (3 years maximum), the incidence can be considered
approximately constant. Therefore, we took uniform densities between di−
and τ isup =min(d
i
+, d
i
11), where d
i
11 is the date of first HIV RNA detectable
measurement.
However, another problem is that patients may have been infected before
the last seronegative date. Fiebig et al. (2003) determined that the HIV
serology becomes positive on average 89 days (95% Confidence Interval =
47–130) after infection. The window of possible infection is thus [τ iinf , τ
i
sup],
where τ iinf = (d
i
− − 130). However, it is less likely that a patient has been
infected 130 days before di− than 5 days before d
i
−, for instance. Therefore,
we assumed linearly increasing densities between τ iinf and d
i
− starting with
fτ i(τ
i
inf) = 0. Thus, the density fτ i is defined by
fτ i(s) =

0, if s≤ τ iinf ,
fτ i(d
i
−)(s− τ iinf)
di− − τ iinf
, if τ iinf ≤ s≤ di−,
fτ i(d
i
−), if s≥ di−,
(2.1)
where fτ i(d
i
−) = 2/(2τ
i
sup− di−− τ iinf) to ensure the continuity of the density
and
∫
fτ i(s)ds= 1.
2.3. Log-likelihood. The model is complicated by the detection limits ζ ij
of assays leading to left-censored observations of HIV RNA for the jth mea-
surement for subject i. We define HIV RNA as the first observable com-
partment (m= 1) and we observe Y ij1 or {Y ij1 < ζ ij}. The left-censored ob-
servations are taken into account as in Thie´baut et al. (2006) and Guedj,
Thie´baut and Commenges (2007a). Noting δij = 1{Y ij1>ζij}
, the full likelihood
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given the random effects ui and the date of infection τ i is given by
LYi|ui,τ i =
ni1∏
j=1
{
1
σ1
√
2pi
exp
[
−1
2
(
Y ij1− g1(X(tij1, ξ˜i))
σ1
)2]}δij
×
{
Φ
(
ζ ij − g1(X(tij1, ξ˜i))
σ1
)}1−δij
×
∏
m=2,M
j=1,nim
{
1
σm
√
2pi
exp
[
−1
2
(
Y ijm− gm(X(tijm, ξ˜i))
σm
)2]}
,
where Φ is the cumulative distribution function of the standard univariate
normal distribution. The individual likelihood given the date of infection is
LOi|τ i =
∫
Rq
LYi|ui,τ i(u)φ(u)du,
where φ is the multivariate normal density of N (0, Iq). To determine the
observed individual likelihood (LOi), we integrate LOi|τ i on [τ iinf ; τ isup]:
LOi =
∫ τ isup
τ iinf
LOi|τ i(s)fτ i(s)ds=
∫ τ isup
τ iinf
∫
Rq
LYi|ui,τ i(u, s)φ(u)fτ i(s)duds.
We note LYi|ui,τ i = logLYi|ui,τ i and LOi = logLOi . The global observed log-
likelihood is LO =
∑
i≤nLOi . The integral on time is calculated by recursive
adaptive Gauss-Legendre quadrature [Berlizov and Zhmudsky (1999)].
2.4. Likelihood maximization. A Newton-like method was used for max-
imizing the likelihood. This method uses the first derivatives of the log-
likelihood (the scores) [Commenges et al. (2006)]. The observed scores can
be obtained by applying twice Louis’ formula [Louis (1982)]:
UOi =
∂LOi
∂θ
= (LOi)−1
∫ τ isup
τ iinf
LOi|τ i(s)UOi|τ i(s)fτ i(s)ds,
where:
UOi|τ i(·) = (LOi|τ i(·))−1
∫
Rq
LYi|ui,τ i(u, ·)UYi|ui,τ i(u)φ(u)du.
The scores UYi|ui,τ i are determined by differentiating LYi|ui,τ i by θ, where
θ = ((φl)l=1,p, (βl)l=1,p,A= (all′)l′≤l≤q, σ = (σl)l≤M
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2.5. A posteriori estimations and distribution of the date of infection.
Individual parameters ξ˜i were estimated by the empirical Bayes estimators
ˆ˜ξi, where ˆ˜ξ
i
l = φˆl + z
i
l βˆl + Aˆuˆ
i and uˆi is the posterior mode of the density of
ui given the data. Then, individual trajectories were predicted by computing
Xˆi =X(t, ˆ˜ξi).
An estimator of the a posteriori distribution of the date of infection, fτ i|Y i ,
can then be computed at the estimated individual parameters
ˆ˜
ξi. We denote
by Y i the vector of measurements for subject i and by fY i|τ i the probability
density function of Y i given the date of infection. Applying Bayes’ formula,
we have
fτ i|Y i(·|Y i) =
fY i|τ i(Y
i|·)fτ i(·)∫ τ isup
τ iinf
fY i|τ i(Y
i|s)fτ i(s)ds
.
3. Models for primary HIV infection.
3.1. Models for the biological system. We considered two ODE models
for HIV infection: the “basic model” and the “productive cells model.” The
“basic model” has three compartments: T (noninfected CD4), T ∗ (produc-
tively infected CD4) and V (free virion) [Nowak et al. (1997b); Stafford et al.
(2000); Perelson (2002)]. This model can be written as
dT
dt
= λ− γV T − µTT,
dT ∗
dt
= γV T − µT ∗T ∗,
dV
dt
= piT ∗ − µV V.
(3.1)
The uninfected CD4 cells enter the blood circulation at rate λ, and die at
the rate µT . They can be infected by the virus at the rate γV . The infected
CD4 die at the rate µT ∗ and produce virions at the rate pi. Virions die at the
rate µV and can also infect other CD4 cells [Figure 1 (a)]. Model parameters
are summarized in Table 1.
We assume that the model is at equilibrium before infection, so at t= 0−,
we have 
T0− =
λ
µT
,
T ∗0− = 0,
V0− = 0.
The initial inoculum of virions is fixed at 10−6 virions/mm3 [Ciupe et al.
(2006) Stafford et al. (2000)], which is equivalent to 5 virions for 5 liters
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Fig. 1. Graphical representation of “the basic model” (a) and “the productive cells
model” (b).
Table 1
Parameters of the dynamic models
Parameter Meaning (per day) Value
λ Rate of T cell production per µL estimated
µT∗ Death rate of T
∗ cells estimated
pi Number of virions per T ∗ cells estimated
µT Death rate of T cells estimated
γ Infection rate of T cells per virion per µL 0.00027 [Davenport et al. (2006);
Wilson et al. (2007)]
µV Clearance of free virions 20.0 [Ramratnam et al. (1999)]
α Rate to become productive cells 1.0 [Kiernan et al. (1990);
Barbosa et al. (1994)]
of blood. The introduction of virions in the system at t = 0 disrupts the
initial stability and the system stabilizes to a new equilibrium if the basic
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reproduction number R0 (R0 =
λγpi
µTµT∗µV
) is higher than 1:
T¯ =
µT ∗µV
γpi
,
T¯ ∗ =
λγpi− µTµT ∗µV
γpiµT ∗
,
V¯ =
λγpi− µTµT ∗µV
γµT ∗µV
.
The second model (the “productive cells model”) distinguishes nonpro-
ductive infected cells (T ∗) and productive infected cells (P ) [Figure 1(b)] as
previously suggested in Nowak et al. (1997a). This second model includes
one more parameter α (the rate to become productive infected cells). The
model can be written as
dT
dt
= λ− γV T − µTT,
dT ∗
dt
= γV T − µT ∗T ∗ − αT ∗,
dP
dt
= αT ∗ − µT ∗P,
dV
dt
= piP − µV V.
(3.2)
The equilibrium before infection is
T0− =
λ
µT
,
T ∗0− = 0,
P0− = 0,
V0− = 0.
After the introduction of virions, the system stabilizes to a new equilibrium
if R0 (R0 =
λγpiα
µTµT∗µV (µT∗+α)
) is higher than 1:
T¯ =
µT ∗µV (µT ∗ + α)
γpiα
,
T¯ ∗ =
λ
µT ∗ +α
− µTµV µT ∗
γpiα
,
P¯ =
α
µT ∗
(
λ
µT ∗ + α
− µTµV µT ∗
γpiα
)
,
V¯ =
piα
µV µT ∗
(
λ
µT ∗ +α
− µTµV µT ∗
γpiα
)
.
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3.2. Statistical models. We can construct statistical models as in Sec-
tion 2.1. We took Ψl(·) = log(·) for all l to ensure positivity of parame-
ters. The individual parameters are ξ˜
i
= (λ˜i, µ˜iT ∗ , p˜i
i, µ˜iT ) with λ˜
i = logλi,
µ˜iT ∗ = logµ
i
T ∗ , p˜i
i = logpii and µ˜iT = logµ
i
T . Because of identifiability issues
[Wu et al. (2008)], the values of the other parameters were taken according to
the literature: µV = 20.0 day
−1 [Ramratnam et al. (1999)] and γ = 0.00027
virions−1 day−1 µL−1 [Davenport et al. (2006); Wilson et al. (2007)]. The
parameter α is fixed at 1 day−1 because the time lag between virus entry
and virus production is about 1 day [Kiernan et al. (1990); Barbosa et al.
(1994)].
The observed components were the base-10 logarithm of HIV RNA load
(number of virions per µL) and the fourth root of total CD4 count (num-
ber of cells per µL). For the “basic model,” g1(X) = log10(V ) and g2(X) =
(T+T ∗)0.25 whereX = (T,T ∗, V ). For the “productive cells model,” g1(X) =
log10(V ) and g2(X) = (T +T
∗+P )0.25 where X = (T,T ∗, P,V ). These trans-
formations are commonly used for achieving normality and homoscedasticity
of measurement error distributions [Thie´baut et al. (2003)]. We have
Y ij1 = g1(X(t
i
j1, ξ˜
i)) + εij1, j = 1, . . . , n
i
1,(3.3)
Y ij2 = g2(X(t
i
j2, ξ˜
i)) + εij2, j = 1, . . . , n
i
2,(3.4)
where εij1 and ε
i
j2 are independent Gaussian with zero mean and variances
σ2
VL
and σ2
CD4 respectively.
3.3. Simulation study. We simulated samples of 100 subjects during pri-
mary HIV infection using the “basic model” for simplicity. The parameter
values were defined according to the estimates of our application (see Tables
1 and 3). For each subject, we simulated the dates of HIV tests and the
date of infection. Dates for the HIV serology tests (negative and positive,
respectively) were simulated according to the prior distribution defined in
Section 2.1 [equation (2.1)]. The subjects had a probability of 0.10 to have
a short window of infection (90 days) with repeated measurements around
the time of viral peak and a probability of 0.90 to have a window of infec-
tion of 200 days with repeated measurements after 150 days post-infection.
The times of measurements tijm were as follows: days 1, 10, 15, 30, 50 and
100 for the short windows and days 150, 200, 240, 280, 300 and 350 for the
others. We included independent random effects for the first two parame-
ters (λ and µT ∗). Therefore, the vector of parameters to be estimated was
(λ˜i, µ˜iT ∗ , p˜i
i, µ˜iT , σλ˜, σµ˜T∗ , σVL, σCD4).
We performed a simulation study to compare the estimates according
to three methods: (i) when the date of infection is fixed as the real date
(RD) or (ii) when it is imputed at the midpoint of the interval defined
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the last negative and the first positive HIV test (DI) and (iii) when the
uncertainty of the date of infection was taken into account with our proposed
method (DUK). We simulated 50 data sets of 100 subjects with the design
described above. For each data set, we estimated parameters with the three
methods and we compared them by computing the mean square errors and
the coverage rates (Table 2). The method using the real date of infection
was used as a reference.
The DUK estimators had a much smaller MSE than the DI estimators and
close to the MSE of the RD estimators. It is not feasible with such computa-
tionally demanding programs to make a large simulation. Fifty replications
are not enough to precisely estimate coverage rates but are enough to show
the superiority of our approach over the approach based on imputing the
date of infection at midpoint. The empirical coverage rates were slightly too
high for RD and DUK probably due to overestimation of the variance of the
parameters.
4. Application to the CASCADE data set.
4.1. The study sample. The study sample came from the Concerted Ac-
tion on SeroConversion to AIDS and Death in Europe (CASCADE) study;
it includes seroconverters from Europe, Canada and Australia. The CAS-
CADE study has been described in detail elsewhere [CASCADE (2003)].
Data were pooled in the 2006 update from 20 participating cohorts. We se-
lected HIV seroconverters if their HIV interval test (delay between the date
Table 2
Mean Square Errors (MSE) and coverage rates of the estimation method in the situations
where the date of infection is known (RD), the date of infection is imputed at the
midpoint (DI) and the uncertainty of the date of infection is taken into account (DUK)
MSE Coverage rate (%)
Parameter RD DI DUK RD DI DUK
λ˜ 0.0030 0.0498 0.0033 100 80 100
µ˜T∗ 0.0098 0.1880 0.0086 100 90 100
p˜i 0.0021 0.0426 0.0115 100 90 98
µ˜T 0.0065 4.0268 0.0023 100 60 100
σλ˜ 0.0014 0.0079 0.0022 100 75 100
σµ˜T∗ 0.0051 0.0143 0.0071 100 90 98
σVL 0.0011 0.0075 0.0007 100 100 100
σCD4 0.0001 0.0688 0.0001 100 100 100
σλ˜ and σµ˜T∗ are the standard deviations of random effect for λ˜ and µ˜T∗ .
σVL and σCD4 are the standard deviations of the observation error of log10(V ) and (T +
T ∗)0.25
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of last seronegative test and the date of first seropositive test) was less than
3 years, if they did not receive any antiretroviral treatment during the first
year following the date of seropositive test and if they had more than 3 mea-
surements of CD4 or viral load during this first year of follow-up with the
first detectable viral load measurement during the first three months after
the date of seropositive test. A total of 761 patients met these criteria.
4.2. Models used. We used the two models defined in Section 3.1. The
vector of natural parameters to be estimated for subject i was ξi = (λi, µiT ∗ ,
pii, µiT ) for the two models. The other parameters were assumed to be known
as described in Section 3.2. The windows for possible dates of infection were
fixed as defined in Section 2.2.
Random effects were selected according to a forward selection procedure.
Starting with a model without random effect, we introduced random effects
successively on each parameter and selected the one leading to the best
likelihood improvement. Then, we added a new random effect and continued
until the new model was not rejected by a likelihood ratio test.
4.3. Results. Selected patients had a median of four measurements for
CD4 and for HIV RNA (InterQuartile Range [IQR] = [3; 5]). Most of the
patients were infected by sex between men (71%). Follow-up was censored
after 1 year beyond seropositive HIV test, resulting in a median follow-up
after the first seropositive test of 195 days (IQR = [119; 260]). The median
of the delay between the dates of last seronegative and first seropositive test
was 170 days (IQR = [91; 273]).
The final models included independent random effects for the first two pa-
rameters. Therefore, the estimated vector of parameters was (λ˜, ˜µT ∗ , p˜i, µ˜T , σλ˜,
σµ˜T∗ , σVL, σCD4) for the two models. Usually, random effects are assumed to
be independent in ODE models [Putter et al. (2002); Samson, Lavielle and
Mentre´ (2006); Huang and Wu (2006); Guedj, Thie´baut and Commenges
(2007a)]. To test a possible correlation between the two random effects in-
cluded in our models, we developed a score test based on our previous work
[Drylewicz, Commenges and Thie´baut (2010)]. For both models, the test
was not significant (p = 0.87 and p = 0.92, respectively). The score test is
presented in Appendix A.
The “productive cells model” fitted better than the “basic model” (AIC =
14,300 vs. 15,010). The improvement brought by this model can be consid-
ered as large according to the criterion D which is the difference of AIC
divided by the total number of observations: D = 15,010−14,3006294 = 0.11 [Com-
menges et al. (2008)]. Estimates of the parameters of the two models are
presented in Table 3.
For the “productive cells model,” on the natural scale, the mean half-life
[log(2)/Death rate] of infected and uninfected cells was 0.40 and 21 days,
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Table 3
Estimated parameters and standard-errors (SE) on logarithmic scale for
the “basic” and the “productive cells” models; for meaning of parameters
see Table 1
Basic model Productive cells model
Parameter Estimate SE Estimate SE
λ˜ 3.49 0.032 3.33 0.034
˜µT∗ 0.62 0.046 0.54 0.045
p˜i 5.27 0.041 6.06 0.036
µ˜T −3.26 0.019 −3.40 0.034
σλ˜ 0.16 0.008 0.41 0.057
σµ˜T∗ 0.42 0.043 0.37 0.052
σVL 0.82 0.017 0.75 0.017
σCD4 0.29 0.012 0.27 0.013
AIC 15,010 14,300
σλ˜ and σµ˜T∗ are the standard deviations of random effect for λ˜ and µ˜T∗ .
σVL and σCD4 are the standard deviations of the observation error of
log10(V ) and (T + T
∗)0.25 for the “basic model” and (T + T ∗ + P )0.25
for the “productive cells model.”
respectively. At the time of the viral peak (median viral load of 5.68 log10
copies/mL, IQR = [5.44; 5.96]), the estimated median number of infected
cells was 64 cells/µL (IQR= [40; 113]). At the same time, the median num-
ber of productive cells/µL was 24 (IQR= [14; 46]) among 557 CD4 cells/µL
(IQR = [460; 658]). The median of the estimated CD4 setpoints was 500
cells/µL (IQR = [396; 627]) which is close to the median of observed set-
points (based on at least one measurement after 365 days available in 430
patients): 470 cells/µL (IQR= [371; 615]). At the same time, the median of
the estimated number of infected cells/µL was 8 (IQR = [6; 12]) including
a median of 3 productive cells/µL (IQR = [2; 5]). The median of viral set-
points was also close to that observed in 403 patients: 4.77 log10 copies/mL
(IQR= [4.59; 4.98]) vs. 4.59 (IQR= [4.04; 5.00]).
We found very different a posteriori individual distributions of the date of
infection depending on the width of the window and the quantity of available
information for each patient. Figure 2 shows the a posteriori distributions
displayed on the window of infection (see Section 2.2), where 0 represents
the last seronegative date for six patients chosen for exhibiting different
shapes of the a posteriori distribution. For patients with data clearly before
the setpoint, the model was able to restrict the possible dates of infection.
For instance, patient 132 had an interval of possible dates of infection of 273
days and our estimation restricted this interval to 90 days. However, for other
patients and especially for some patients with a wide interval between last
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Fig. 2. A posteriori individual distributions of the date of infection for patients 6, 41,
55, 66, 132 and 652 from the “productive cells model,” where day 0 is the date of last
negative HIV test.
negative and first positive HIV serology test, the a posteriori distribution had
local maxima. Analysis of marker dynamics according to the local maxima
suggested quite different possibilities according to the available information
(Figure 3).
For each patient, we took the date with the highest probability and plot-
ted predicted individual trajectories for each marker from this date. The fits
of the model were satisfactory. The estimated trajectories are in agreement
with those reported in the literature [Little et al. (1999); Lindback et al.
(2000); Stafford et al. (2000)]. Individual predicted fits and observed values
are shown in Figure 4 for six patients. We studied the distribution of residu-
als and the agreement between predictions and observations for plasma HIV
RNA and CD4 count in Appendix B.
5. Discussion. In this paper we present a method for estimating param-
eters of random effects models based on differential equations when the
origin of time is unknown, taking also into account unbalanced data and
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Fig. 3. Predicted fits from the two most probable dates of infection [ (a) the global max-
imum and (b) the local maximum] and observed values of HIV RNA level and total CD4
count for patient 6 from the “productive cells model.”
left-censored observations. This method was applied to a cohort of HIV pa-
tients during primary infection using repeated measurements of two markers:
plasma HIV RNA and CD4+ T cell counts. The model gave reasonable fits
although the kinetics of the markers was very complex due to nonlinear in-
teraction between the virus and the target cells. Thanks to the population
approach, we were able to describe the dynamics of markers during primary
infection using data from several hundred patients.
Predictions were obviously driven by the structure of the ODE system
that is based on biological knowledge. Compared to a descriptive model, this
mechanistic approach brings additional information. Typically, solutions of
ODE systems led to oscillatory trajectories [Volterra (1926)]: these oscilla-
tions are dampened as time passes so that the trajectory gets closer to the
steady state value. Observations are partly consistent with the oscillating
behavior. The peak of viral load, the reality of which is generally admitted,
is nothing but the first oscillation. It can be noted that the oscillations are
generally more dampened for more complex systems [Burg et al. (2009)]. In
conclusion, the oscillatory trajectories produced by our model are for a part
the expression of a real phenomenon.
Predicted viral and CD4 setpoints (defined as markers values at equilib-
rium) were quite similar to those that could be observed. Interestingly, the
estimated value of infected cells (that are not observed) was in agreement
with previous studies reporting a low concentration of productive infected
cells [Chun et al. (1997)].
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Fig. 4. Individual predicted fits from the most probable date of infection and observed
values of HIV RNA level and total CD4 count for patients 6, 41, 55, 66, 132 and 652 from
the “productive cells model,” where day 0 is the date of last negative HIV test.
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Because the approach was based on a mechanistic model, the parameters
have biological meanings. For instance, the mean half-life of infected cells was
estimated at 0.40 day. Previous estimations of this parameter were mainly
performed in patients treated by antiretroviral therapy. These estimations
varied from 0.7 day to 1.8 day according to the type of treatment and the
type of model used [Perelson et al. (1996); Faulkner et al. (2003); Huang and
Wu (2006); Huang (2007)]. Similarly, it is interesting to note that our esti-
mate of virus production (428 virions/cell/day) is of the same order as what
has been reported [Dimitrov et al. (1993); Levy et al. (1996); Haase (1999)].
However, the biological relevance of the present model could still be ques-
tioned with regards to other processes that have been ignored. For instance,
the cytotoxic T-cell response plays a role in the control of the infection and
the decrease of the viral load by killing the infected cells [Stafford et al.
(2000)], although the efficiency of this immunological response is debated
[Asquith and McLean (2007)]. Moreover, our estimate of target CD4 cells
half-life is a mixture of the half-life of quiescent cells and that of activated
cells [Mclean and Michie (1995); Vrisekoop et al. (2008)].
The uncertainty on the date of infection was taken into account to improve
the accuracy of the estimates as compared to performing simple imputations.
In addition, we were able to derive the individual posterior distribution of
the date of infection according to the model. When enough information is
available the date of infection can be estimated with good accuracy (Fig-
ure 2). The sensitivity of the estimates to the assumptions about the priors
[equation (2.1) in Section 2.2] was roughly proportional to the amount of
data available as illustrated by the posterior infection time distribution of
patient 41 compared to patient 66 (Figure 2). We also performed a sensi-
tivity analysis which demonstrated a certain robustness of the method. The
lower bound of the infection time distribution could be better defined by us-
ing additional information such as antibody dynamics. Unfortunately, this
information was not available in the present data set.
The main limitation for the use of dynamical models is the parameter
identifiability that led us to fix the value of γ (infection rate) and µV (viral
clearance). The clearance was fixed to 20 day−1 according to recent studies
with highly repeated measures of HIV RNA after initiation of antiretrovi-
ral treatment [Perelson et al. (1997); Ramratnam et al. (1999)]. The chosen
value of µV may influence the estimation of other parameters such as pi, as
the viral setpoint is essentially determined by the ratio pi
µV
[Nowak et al.
(1997a)]. Identifiability may be improved by measuring more compartments
such as infected cells or by increasing the number of repeated measurements
[Guedj, Thie´baut and Commenges (2007b)]. This is an important point to
consider in future studies, as the issue of identifiability precludes the com-
parison with more complex models.
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Table 4
Notation used in the manuscript
Notation Meaning
i (1, . . . , n) Subject
Xi(t) Vector of the K components of the model at time t
ξi Vector of p individual natural parameters
ξ˜i =Ψ(ξi) Vector of p individual transformed parameters
φl Intercept of the lth parameter
zil Vectors of explanatory variables associated to the fixed effects of the lth
biological parameter
βil Vectors of regression coefficients associated to the fixed effects
bi =Aui Individual vector of random effects of dimension q
A= (al′′l′)l′≤l′′≤q Lower triangular matrix with positive diagonal elements AA
′ =Σ
(Cholesky decomposition)
Y ijm jth measurement of the mth compartment of subject i
dijm Date of measurement of Y
i
jm
τ i Date of infection of subject i
tijm Time between τ
i and dijm
gm(·) (m= 1, . . . ,M) Nonlinear function for the mth observed compartment
εijm Gaussian measurement errors with zero mean and variances σ
2
m
di− Date of last negative HIV test of subject i
di+ Date of first positive HIV test of subject i
fτi Density of infection date τ
i
[τ iinf , τ
i
sup] Support of the density fτi
ζij Detection limit of the jth measurement of subject i
Finally, this method can be applied in other areas where either the model
is simpler or the amount of measured information greater, so that identifia-
bility is less an issue.
APPENDIX A: SCORE TEST FOR COVARIANCE OF RANDOM
EFFECTS
In Drylewicz, Commenges and Thie´baut (2010), we have developed score
tests for explanatory variables and variance of random effects in complex
models. We propose here to develop a test for the covariance parameter of
random effects. We assume that the date of infection is known and introduce
notation for a conventional nonlinear model. For subject i with i= 1, . . . , n,
we consider a model which specifies the distribution of the observed vector
Y
i = (Y ij , j = 1, . . . , n
i):
Y ij = g(t
i
j , ξ˜
i
) + εij , j = 1, . . . , n
i,
where Y ij is the jth measurement for subject i at the time t
i
j , and the ε
i
j
are independent Gaussian measurement errors with zero mean and vari-
ances σ2. The function g(·) is a twice differentiable (generally nonlinear)
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function. The individual parameters ξ˜
i
= (ξ˜l
i
, l = 1, . . . , p) are modeled as a
linear form: ξ˜il = φl+ b
i
l+ z
i
lβl, where φl is the intercept, and z
i
l is the vector
of explanatory variables associated to the fixed effects of the lth parame-
ter. The βl’s are vectors of regression coefficients. We assume b
i ∼N (0,Σ),
where bi is the individual vector of random effects of dimension q. Let
A= (al′′l′)l′≤l′′≤q be the lower triangular matrix with positive diagonal ele-
ments such that AA′ =Σ (Cholesky decomposition). We can write bi =Aui
with ui ∼ N (0, Iq). We denote by θ = (φl,A,βl, l = 1, . . . , p) the set of pa-
rameters of the model and by Lθ
Yi|ui
(Y i|u) the likelihood of observations for
subject i given that the random effects ui take the value u. Given ui, the
Y ij are independent, so LθYi|ui(Y i|u) =
∏
j LθYi
j
|ui
(Y ij |u), where
LθYij |ui(Y
i
j |u) =
1√
2piσ
exp
{
−(Y
i
j − g(tij , ξ˜
i
))2
2σ2
}
.
The observed log-likelihood for subject i is
Lθi = log
∫
Rq
LθYi|ui(Y i|u)φ(u)du,
where φ is the multivariate normal density of N (0, Iq). We denote L =
Lθ1 + · · ·+Lθn, the global log-likelihood.
For simplicity and for illustrating our specific case, we assume that only
two random effects are included in the model (uil and u
i
l′). We want to test
whether bil and b
i
l′ are independent. The null hypothesis H0 is “all′ = 0”. The
scores U ill′ (individual score for all′) are obtained integrating U
i
ll′|ui
using
Louis’ formula [Louis (1982)]:
U ill′ = (LOi)−1
∫
R2
LθYi|ui(u)U ill′|ui(u)φ(u)du,
where
U ill′|ui(u) =
∑
j=1,ni
1
σ2
(Y ij − g(X(tij , ξ˜i)))
(
uil′all
∂g(X(tij , ξ˜
i))
∂ξil
)
.
Under the null hypothesis, we propose the following statistic:
S =
U•
ll′|H0√
V̂arU•
ll′|H0
,
where U•
ll′|H0
is the sum of individual scores U ill′ calculated under H0 and
V̂arU•
ll′|H0
is a consistent estimator of VarU•
ll′|H0
. S has an asymptotic stan-
dard normal distribution under H0. We take V̂arU
•
ll′|H0
=
∑
i=1,nU
i2
ll′|H0
.
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Fig. 5. Residuals of fourth-root of CD4 count with respect to predictions ( left) and ob-
servations with respect to predictions ( right).
Fig. 6. Residuals of HIV RNA with respect to predictions ( left) and observations with
respect to predictions ( right), the left-censored measurements of HIV RNA have been ex-
cluded (72 among 3038 measurements).
APPENDIX B: GOODNESS OF FIT
Figures 5 and 6 present the residuals with respect to the predictions and
the observations with respect to the predictions for the fourth root of CD4
count and the base 10-logarithm of HIV RNA load. The residuals are com-
puted using empirical bayes and predictions from the most probable date
of infection for each patient. We excluded left-censored HIV RNA measure-
ments (72 among 3038 measurements).
The residuals are well distributed around 0 and there is a good agreement
between predictions and observations for both HIV RNA and CD4 count.
The four outliers observed on the left of HIV RNA figures are due to patients
having only one detectable measurement of HIV RNA during their follow-up
and the only detectable value was low (<3 log10 copies/mL).
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